We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

109 hedge funds and large institutions have $571M invested in Vanda Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 32 increasing their positions, 34 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

331% more call options, than puts

Call options by funds: $56.9M | Put options by funds: $13.2M

267% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 9

45% more capital invested

Capital invested by funds: $393M → $571M (+$178M)

27% more funds holding

Funds holding: 86 → 109 (+23)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

6% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 34

Holders
109
Holders Change
+23
Holders Change %
+26.74%
% of All Funds
3.15%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
33
Increased
32
Reduced
34
Closed
9
Calls
$56.9M
Puts
$13.2M
Net Calls
+$43.7M
Net Calls Change
+$24.8M

Top Buyers

Rank Fund Capital Flow
1
PC
Paulson & Co
New York
+$19.8M
2
CCM
Consonance Capital Management
New York
+$16M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$14.5M
4
State Street
State Street
Massachusetts
+$14M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$7.73M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$9.65M
2
Wells Fargo
Wells Fargo
California
-$8.96M
3
VM
VHCP Management
New York
-$8.92M
4
O
OrbiMed
New York
-$7.5M
5
BBA
Baker Bros. Advisors
New York
-$4.91M
Name Holding Trade Value Shares
Change 		Change in
Stake
QBFM
26
QS Batterymarch Financial Management
New York
$3.91M – – –
Balyasny Asset Management
27
Balyasny Asset Management
Illinois
$3.66M +$3.21M +225,480 New
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
$3.59M +$2.4M +169,018 +326%
BCM
29
Bridgeway Capital Management
Texas
$3.49M -$474K -33,308 -13%
TAM
30
THB Asset Management
Connecticut
$3.38M +$2.96M +207,900 New
Hudson Bay Capital Management
31
Hudson Bay Capital Management
Connecticut
$3.36M +$2.94M +206,909 New
Millennium Management
32
Millennium Management
New York
$3.25M -$9.65M -678,530 -77%
Geode Capital Management
33
Geode Capital Management
Massachusetts
$3.09M +$72.7K +5,113 +3%
Principal Financial Group
34
Principal Financial Group
Iowa
$3.08M -$227K -15,985 -8%
OAM
35
Oxford Asset Management
United Kingdom
$2.92M +$2.56M +180,017 New
Marshall Wace
36
Marshall Wace
United Kingdom
$2.76M +$2.42M +170,104 New
Connor, Clark & Lunn Investment Management (CC&L)
37
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$2.6M +$980K +68,907 +91%
LOAMU
38
Lombard Odier Asset Management (USA)
New York
$2.44M – – –
GC
39
Guggenheim Capital
Illinois
$2.38M -$171K -12,026 -8%
Group One Trading
40
Group One Trading
Illinois
$2.25M -$1.17M -82,633 -37%
Wellington Management Group
41
Wellington Management Group
Massachusetts
$2.05M +$1.8M +126,400 New
HCMT
42
Highland Capital Management (Texas)
Texas
$2M +$1.75M +123,090 New
GS
43
Gagnon Securities
New York
$1.81M -$329K -23,158 -17%
SGAM
44
Smith Group Asset Management
Texas
$1.78M -$9.23K -649 -0.6%
IHM
45
Iguana Healthcare Management
New York
$1.63M +$1.42M +100,000 New
Credit Agricole
46
Credit Agricole
France
$1.58M +$1.38M +97,226 New
BIM
47
BlackRock Investment Management
Delaware
$1.49M +$9.94K +699 +0.8%
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
$1.49M -$2.11M -148,508 -62%
CS
49
Credit Suisse
Switzerland
$1.33M +$583K +41,035 +101%
AQR Capital Management
50
AQR Capital Management
Connecticut
$1.21M – – –
1
2
3 4 5

VNDA Hedge Fund Activity: Q1 2014 in Review

109 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2014, worth a combined $571M — up 45% from $393M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new VNDA positions and 9 closed out — a net gain of 24 holders — while 32 added to existing stakes and 34 trimmed.

The largest buyer was Paulson & Co, opening a new position worth an estimated $19.8M. The largest seller was Millennium Management, cutting an estimated $9.65M.

  • 109 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2014, up from 86 in Q4 2013.
  • Funds reported $571M of Vanda Pharmaceuticals stock for Q1 2014, up 45% quarter-over-quarter.
  • 33 funds opened new Vanda Pharmaceuticals positions in Q1 2014 and 9 closed out, a net change of +24 holders.
  • The largest Vanda Pharmaceuticals buyer in Q1 2014 was Paulson & Co, an estimated $19.8M added.
  • The largest Vanda Pharmaceuticals seller in Q1 2014 was Millennium Management, an estimated $9.65M sold.

Based on aggregated 13F filings for Q1 2014.